Table 2.
Overview of the pharmacological modulation of sirtuins with a therapeutic effect in cancer, neurodegenerative diseases (Alzheimer’s disease—AD, Huntington’s disease—HD, Parkinson’s disease—PD, Amyotrophic Lateral Sclerosis—ALS, Multiple Sclerosis—MS) and type 2 diabetes (T2D).
| Sirtuin | Cancer | Neurodegenerative Diseases (AD, HD, PD, ALS, MS) |
Type 2 Diabetes (T2D) |
|---|---|---|---|
| SIRT-1 | Activation or inhibition (depending on cancer type) | AD: activation HD: inhibition PD: activation ALS: inhibition MS: inhibition |
Activation |
| SIRT-2 | Inhibition | AD: inhibition HD: inhibition PD: inhibition ALS: - MS: - |
Inhibition |
| SIRT-3 | Activation or inhibition (depending on cancer type) | AD: activation HD: - PD: activation ALS: - MS: activation |
Activation |
| SIRT-4 | - | - | - |
| SIRT-5 | Activation or inhibition (depending on cancer type) | - | - |
| SIRT-6 | Activation or inhibition (depending on cancer type) | AD: - HD: - PD: inhibition ALS: - MS: inhibition |
Inhibition |
| SIRT-7 | Inhibition (depending on cancer type) |
- | - |